Incyte, Genentech to assess combination of two new cancer immunotherapies
The clinical trial is designed to evaluate the safety, tolerability and preliminary efficacy of Incyte’s oral indoleamine dioxygenase-1 (IDO1) inhibitor, INCB24360, in combination with Genentech’s PD-L1 immune checkpoint